Can Hou

Dr. Can Hou


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
JHJun-Yu Huo
Jun-Yu Huo
CHCan Hou
Can Hou
FJFang Jia
Fang Jia
CXCong Xue
Cong Xue
XLXiao-Long Li
Xiao-Long Li
XZXiaoYing Zhang
XiaoYing Zhang

12 August 2025 in Cardiology
Verified
Journal Article
Open access
SYSi Yan
Si Yan
ZFZhichao Fang
Zhichao Fang
XXXin Xue
Xin Xue
CHCan Hou
Can Hou
XYXiaoyu Yang
Xiaoyu Yang
Background: Myocardial infarction (MI) and cancer collectively account for over 50% of global mortality. Recent studies have revealed multiple associations between these two diseases, including chronic inflammation and oxidative stress, with a particular focus on hypoxia-mediated signaling pathways. In ischemic myocardium, oxygen deprivation triggers apoptosis, fibrosis, and pathological tissue reorganization, in the tumor microenvironment (TME), hypoxia drives angiogenesis, metabolic reprogramming, and immune evasion. Therefore, identifying hypoxia-related differentially expressed genes in MI may provide potential therapeutic targets for both conditions. Methods: Sequencing data from MI patients were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the “limma” package in R.Weighted gene co-expression network analysis (WGCNA) was then employed to screen for a set of potential hub genes associated with hypoxia. Functional enrichment analysis was performed on these hub genes. The expression levels and stability of the hub genes were subsequently validated in a new dataset. Finally, transcriptional regulatory analysis and immune infiltration analysis were conducted for the hub genes, and their expression levels and prognostic values in various cancers were evaluated. Results: In MI samples, nine genes, namely Immediate Early Response 3 (IER3), Heme Oxygenase 1 (HMOX1), Cyclin Dependent Kinase Inhibitor 1A (CDKN1A), Plasminogen Activator Urokinase Receptor (PLAUR), MAF BZIP Transcription Factor F (MAFF), Solute Carrier Family 2 Member 3 (SLC2A3), Jun Proto-Oncogene (JUN), Transforming Growth Factor Beta Induced (TGFBI), and 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), were found to be significantly dysregulated and were closely associated with the occurrence of various cancers. Pan-cancer analysis further revealed that these genes are correlated with cancer prognosis. Immune analysis also observed their associations with resting CD4+ memory T cells and Gamma Delta T cells in TME. Conclusions: IER3, HMOX1, CDKN1A, PLAUR, MAFF, SLC2A3, JUN, TGFBI, and PFKFB3 are potential biomarkers for MI and cancer. Research on hypoxia-related genes (HRGs) may provide new therapeutic targets for these two diseases.